source
- RevMed earns standing ovation at ASCO for pancreatic cancer data while Akeso faces cautionAt the American Society of Clinical Oncology meeting, RevMed captured audience attention with data on its pancreatic cancer therapy, earning a rare standing ovation. In contrast, presentations fro…
- Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in IndiaResearchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…